Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions.Target Discovery, Research Collaboration and Option Agreement • March 5th, 2020 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations
The purpose of this letter (this “Letter Agreement”) is to memorialize our discussions and the agreement reached between Incyte and Syros with respect to certain issues related to the Target Discovery, Research Collaboration and Option Agreement between Incyte Corporation (“Incyte”) and Syros Pharmaceuticals, Inc., (“Syros”) dated January 8, 2018 (the “Agreement”). Capitalized terms not defined herein shall have the meanings set forth in the Agreement.
Confidential Materials omitted and filed separately with theTarget Discovery, Research Collaboration and Option Agreement • March 12th, 2018 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Target Discovery, Research Collaboration and Option Agreement (this “Agreement”) is made effective as of January 8, 2018 (the “Effective Date”) by and between Syros Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 620 Memorial Drive, Suite 300, Cambridge, Massachusetts 02139 (“Syros”) and Incyte Corporation, a Delaware corporation having its principal place of business at 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (“Incyte”). Syros and Incyte are each referred to herein by name or as a “Party” or, collectively, as “Parties”.
